- Home
- SMHI vs ACRS Comparison
SMHI vs ACRS Comparison
Compare SMHI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- ACRS
- Stock Information
- Founded
- SMHI 1989
- ACRS 2012
- Country
- SMHI United States
- ACRS United States
- Employees
- SMHI N/A
- ACRS N/A
- Industry
- SMHI Marine Transportation
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SMHI Consumer Discretionary
- ACRS Health Care
- Exchange
- SMHI Nasdaq
- ACRS Nasdaq
- Market Cap
- SMHI 142.2M
- ACRS 127.6M
- IPO Year
- SMHI N/A
- ACRS 2015
- Fundamental
- Price
- SMHI $4.97
- ACRS $1.26
- Analyst Decision
- SMHI
- ACRS Strong Buy
- Analyst Count
- SMHI 0
- ACRS 7
- Target Price
- SMHI N/A
- ACRS $10.67
- AVG Volume (30 Days)
- SMHI 124.5K
- ACRS 807.1K
- Earning Date
- SMHI 04-30-2025
- ACRS 05-08-2025
- Dividend Yield
- SMHI N/A
- ACRS N/A
- EPS Growth
- SMHI N/A
- ACRS N/A
- EPS
- SMHI N/A
- ACRS N/A
- Revenue
- SMHI $264,089,999.00
- ACRS $17,777,000.00
- Revenue This Year
- SMHI $8.07
- ACRS N/A
- Revenue Next Year
- SMHI $7.29
- ACRS $425.96
- P/E Ratio
- SMHI N/A
- ACRS N/A
- Revenue Growth
- SMHI N/A
- ACRS N/A
- 52 Week Low
- SMHI $3.63
- ACRS $0.95
- 52 Week High
- SMHI $15.36
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SMHI 52.97
- ACRS 43.64
- Support Level
- SMHI $4.32
- ACRS $1.20
- Resistance Level
- SMHI $4.99
- ACRS $1.46
- Average True Range (ATR)
- SMHI 0.37
- ACRS 0.11
- MACD
- SMHI 0.04
- ACRS 0.02
- Stochastic Oscillator
- SMHI 61.50
- ACRS 41.77
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.